section name header

Pronunciation

a-MOX-a-peen

Classifications

Therapeutic Classification: antidepressants

Indications

BEERS REMS


Unlabeled Use:
  • Anxiety, insomnia, neuropathic and chronic pain syndromes.

Action

  • Potentiates the effects of serotonin and norepinephrine in the CNS.
  • Has significant anticholinergic properties.
  • Also has antianxiety effect related to sedative properties.
Therapeutic effects:
  • Antidepressant and antianxiety action.

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Widely distributed; enters breast milk.

Protein Binding: 92% bound to plasma proteins.

Metabolism/Excretion: Extensively metabolized by the liver, primarily by the CYP2D6 isoenzyme; the CYP2D6 enzyme system exhibits genetic polymorphism (7% of population may be poor metabolizers and may have significantly amoxapine concentrations and an risk of adverse effects)..

Half-Life: 8 hr.

Time/Action Profile

(antidepressant effect)

ROUTEONSETPEAKDURATION
POwithin 1–2 wk2–6 wkdays–wks





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, ARRHYTHMIAS

Derm: photosensitivity, rash

EENT: blurred vision, dry eyes

Endo: gynecomastia, sexual dysfunction

GI: constipation, dry mouth, paralytic ileus

GU: testicular swelling, urinary retention

Hemat: blood dyscrasias

Metab: appetite, weight gain

Neuro: fatigue, sedation, extrapyramidal reactions, NEUROLEPTIC MALIGNANT SYNDROME, tardive dyskinesia

Misc: fever

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Asendin